Streetbeat News

Analyst Ratings

ITCI

In the past 3 months, 14 analysts have published their opinions on Intra-Cellular Therapies (NASDAQ:ITCI) stock, with an average 12-month price target of $76.29. The average price target has increased by 3.88% over the past month.

Portfolio Pulse from Benzinga Insights

June 22, 2023 | 5:00 pm

DALXF

Raymond James analyst Jeremy Mccrea maintains a Outperform rating on Spartan Delta (OTC:DALXF) and lowers the price target from C$19 to C$6.5.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:58 pm

KXSCF

RBC Capital analyst Paul Treiber maintains an Outperform rating on Kinaxis (OTC:KXSCF) and raises the price target from C$210 to C$220.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:55 pm

NWHUF

Scotiabank analyst Mario Saric maintains a Sector Perform rating on Northwest Healthcare REIT (OTC:NWHUF) and lowers the price target from C$11 to C$9.5.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:52 pm

CP

Scotiabank analyst Konark Gupta maintains an Outperform rating on Canadian Pacific Kansas (NYSE:CP) and raises the price target from C$122 to C$124.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:47 pm

APYRF

Scotiabank analyst Mario Saric maintains an Outperform rating on Allied Properties REIT (OTC:APYRF) but lowers the price target from C$35 to C$31.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:43 pm

AMZN

JP Morgan analyst Doug Anmuth reiterates an Overweight rating on Amazon.com (NASDAQ:AMZN) and maintains a $145 price target.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:39 pm

DLTR

Deutsche Bank analyst Krisztina Katai maintains a Buy rating on Dollar Tree (NASDAQ:DLTR) and raises the price target from $161 to $162.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:35 pm

EQIX

Equinix shares dropped after a disappointing analyst day, with management suggesting a deceleration from current elevated levels. Analyst Timothy Horan downgraded the rating for Equinix from Outperform to Perform, while keeping the price target unchanged at $768.

Portfolio Pulse from Priya Nigam

June 22, 2023 | 4:35 pm

ACN

Baird analyst David Koning reiterates a Neutral rating on Accenture (NYSE:ACN) and maintains a $322 price target.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:33 pm